REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising new combo targets rare infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with chemotherapy for infants and young children with a hard-to-treat leukemia that has returned or not responded to treatment. The drug targets a specific genetic change (KMT2A rearrangement) that drives the cancer. The goal …
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 11:21 UTC
-
New combo therapy shows promise for Tough-to-Treat leukemia
Disease control OngoingThis early-stage study tests a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in adults with a type of leukemia that has returned or not responded to standard treatment. The main goals are to find the safest dose and identify side effects. Abou…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:19 UTC
-
New hope for kids with relapsed leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC